PMID- 26043796
OWN - NLM
STAT- MEDLINE
DCOM- 20161021
LR  - 20181202
IS  - 1525-1594 (Electronic)
IS  - 0160-564X (Linking)
VI  - 40
IP  - 2
DP  - 2016 Feb
TI  - Systematic Review of Phosphodiesterase-5 Inhibitor Use in Right Ventricular 
      Failure Following Left Ventricular Assist Device Implantation.
PG  - 123-8
LID - 10.1111/aor.12518 [doi]
AB  - Our aim was to identify relevant literature supporting the use of 
      phosphodiesterase-5 (PDE5) inhibitors in patients with persistent pulmonary 
      hypertension with signs of postprocedural right ventricular (RV) dysfunction 
      following left ventricular assist device (LVAD) implantation. We searched 
      MEDLINE, SCOPUS, and Web of Science from inception through November 27, 2014 for 
      citations evaluating patients with end-stage heart failure necessitating LVAD, 
      continuous and pulsatile, who received a PDE5 inhibitor to prevent RV failure. 
      Outcomes of interest included changes in mean pulmonary artery pressure, 
      pulmonary vascular resistance, central venous pressure, cardiac index, and mean 
      arterial pressure. Results are presented qualitatively. Four citations (n = 83 
      patients) were included. These included a single case report, two retrospective 
      case series, and a prospective open-label study with a historical control. All 
      four studies utilized the PDE5 inhibitor sildenafil with various doses for up to 
      3 months. Sildenafil routinely reduced mean pulmonary artery pressures as soon as 
      90 min after administration. Reductions in pulmonary vascular resistance were 
      also seen shortly after the procedure and maintained through 12-15 weeks. While 
      one study saw improvements in postoperative central venous pressures, another did 
      not. Evidence supporting PDE5 inhibitor use to attenuate RV failure in patients 
      requiring an LVAD is weak.
CI  - Copyright (c) 2015 International Center for Artificial Organs and Transplantation 
      and Wiley Periodicals, Inc.
FAU - Baker, William L
AU  - Baker WL
AD  - Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, 
      Storrs, CT, USA.
FAU - Radojevic, Joseph
AU  - Radojevic J
AD  - Center for Advanced Heart Failure & Transplant, Department of Cardiology, 
      Hartford Hospital, Hartford, CT, USA.
FAU - Gluck, Jason A
AU  - Gluck JA
AD  - Center for Advanced Heart Failure & Transplant, Department of Cardiology, 
      Hartford Hospital, Hartford, CT, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20150604
PL  - United States
TA  - Artif Organs
JT  - Artificial organs
JID - 7802778
RN  - 0 (Phosphodiesterase 5 Inhibitors)
SB  - IM
MH  - Blood Pressure/*drug effects
MH  - Heart Failure/complications/*surgery
MH  - *Heart-Assist Devices/adverse effects
MH  - Humans
MH  - Hypertension, Pulmonary/complications/drug therapy
MH  - Phosphodiesterase 5 Inhibitors/*therapeutic use
MH  - Treatment Outcome
MH  - Vascular Resistance/drug effects
MH  - Ventricular Dysfunction, Right/complications/*drug therapy
OTO - NOTNLM
OT  - Left ventricular assist device
OT  - Phosphodiesterase-5 inhibitor
OT  - Right ventricular dysfunction
EDAT- 2015/06/06 06:00
MHDA- 2016/10/22 06:00
CRDT- 2015/06/06 06:00
PHST- 2015/06/06 06:00 [entrez]
PHST- 2015/06/06 06:00 [pubmed]
PHST- 2016/10/22 06:00 [medline]
AID - 10.1111/aor.12518 [doi]
PST - ppublish
SO  - Artif Organs. 2016 Feb;40(2):123-8. doi: 10.1111/aor.12518. Epub 2015 Jun 4.